CompletedPhase 1ketamine

Absolute Bioavailability and Nasopharyngeal Absorption of Intranasal Ketamine

NCT ID

NCT00520169

Target Enrollment

32 participants

Start Date

2007-07

Est. Completion

2007-09

About This Study

This is an open label, single-center study to determine the absolute bioavailability and nasopharyngeal absorption of PMI-150 (intranasal ketamine) 30 mg in healthy adult volunteers.

Conditions Studied

Healthy

Interventions

•intranasal ketamine

Eligibility

Age:18 Years - N/A

Healthy Volunteers:Yes

View full eligibility criteria

Inclusion Criteria:

* Healthy adults

Exclusion Criteria:

* under 18 years

Study Locations (1)

Javelin Pharmaceuticals

Cambridge, Massachusetts, United States